SEC Company Response from Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251) (CTXR) — Jul 28, 2017
Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)
Date: July 28, 2017 · CIK: 0001506251 · Accession: 0001477932-17-003566
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-217956
Letter
ctxr_corresp.htmCITIUS PHARMACEUTICALS, INC.
11 Commerce Drive, First Floor
Cranford, New Jersey 07016
July 28, 2017
Via EDGAR Delivery
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re:
Citius Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-217956
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Citius Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective date of the above-referenced registration statement (the “Registration Statement”) so as to become effective on Tuesday, August 1, 2017, at 5:00 p.m. Eastern Time, or as soon thereafter as practicable.
Please be advised that the amount of compensation to be paid to the underwriters and any other arrangements among the Registrant and the underwriters and other broker-dealers participating in the distribution, as described in the Registration Statement, have been reviewed to the extent required by the Financial Industry Regulatory Authority and such Authority has issued a statement expressing no objections to the compensation and other arrangements.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Erica Jackson at (919) 781-4000. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to Ms. Jackson via email at ejackson@wyrick.com.
Very truly yours,
CITIUS PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm ctxr_corresp.htmCITIUS PHARMACEUTICALS, INC. 11 Commerce Drive, First Floor Cranford, New Jersey 07016 July 28, 2017 Via EDGAR Delivery Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Citius Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-217956 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Citius Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective date of the above-referenced registration statement (the “Registration Statement”) so as to become effective on Tuesday, August 1, 2017, at 5:00 p.m. Eastern Time, or as soon thereafter as practicable. Please be advised that the amount of compensation to be paid to the underwriters and any other arrangements among the Registrant and the underwriters and other broker-dealers participating in the distribution, as described in the Registration Statement, have been reviewed to the extent required by the Financial Industry Regulatory Authority and such Authority has issued a statement expressing no objections to the compensation and other arrangements. Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Erica Jackson at (919) 781-4000. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to Ms. Jackson via email at ejackson@wyrick.com. Very truly yours, CITIUS PHARMACEUTICALS, INC. By: /s/ Myron Holubiak Myron Holubiak Chief Executive Officer